IMDEA Nanociencia hosts the final workshop of the project NoCanTher: magnetic nanoparticle-based approaches towards the clinic
The NOCANTHER consortium of has celebrated the final workshop of the project, a European project involving 12 partners from 5 countries towards the upscaling of a nanotherapy for early clinical phases of pancreatic cancer.
The meeting, attended by over 80 in-person and online attendees from 16 countries, has revised the NOCANTHER project 6-year journey, from the design of nanoparticles in the laboratory, to the evaluation of the nanoparticles in a clinical study. The workshop was celebrated jointly with the European project SAFE-N-MEDTECH, and was an excellent opportunity for networking and exchange of ideas.
The NOCANTHER project has successfully achieved the ultimate goal that was initiated over 11 years ago during the FP7 project MULTIFUN: the first patients being enrolled in a clinical study, led by the Vall d’Hebron Institute of Oncology. The project has now officially finished, but partners continue looking forward to the results of this promising clinical study, with an eye of the application on new therapeutic avenues with locally advanced pancreatic cancer.
NOCANTHER project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 685795.
Prof. Álvaro Somoza
Oficina de Comunicación de IMDEA Nanociencia
Source: IMDEA Nanociencia.